188 related articles for article (PubMed ID: 31151985)
21. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
[TBL] [Abstract][Full Text] [Related]
23. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
[TBL] [Abstract][Full Text] [Related]
24. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
25. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
[TBL] [Abstract][Full Text] [Related]
26. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
28. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.
Escribano L; Alvarez-Twose I; Sánchez-Muñoz L; Garcia-Montero A; Núñez R; Almeida J; Jara-Acevedo M; Teodósio C; García-Cosío M; Bellas C; Orfao A
J Allergy Clin Immunol; 2009 Sep; 124(3):514-21. PubMed ID: 19541349
[TBL] [Abstract][Full Text] [Related]
29. Digital PCR: A Sensitive and Precise Method for
Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Simonitsch-Klupp I; Mitterbauer-Hohendanner G; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
Clin Chem; 2018 Mar; 64(3):547-555. PubMed ID: 29237714
[TBL] [Abstract][Full Text] [Related]
30. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
[TBL] [Abstract][Full Text] [Related]
31. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
32. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Class SV; Eisenwort G; Simonitsch-Klupp I; Esterbauer H; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
Haematologica; 2020; 105(2):366-374. PubMed ID: 31018976
[TBL] [Abstract][Full Text] [Related]
33. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
34. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
35. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
37. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Martelli M; Monaldi C; De Santis S; Bruno S; Mancini M; Cavo M; Soverini S
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32498255
[TBL] [Abstract][Full Text] [Related]
38. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive mutational profiling in advanced systemic mastocytosis.
Schwaab J; Schnittger S; Sotlar K; Walz C; Fabarius A; Pfirrmann M; Kohlmann A; Grossmann V; Meggendorfer M; Horny HP; Valent P; Jawhar M; Teichmann M; Metzgeroth G; Erben P; Ernst T; Hochhaus A; Haferlach T; Hofmann WK; Cross NC; Reiter A
Blood; 2013 Oct; 122(14):2460-6. PubMed ID: 23958953
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis.
Riffel P; Jawhar M; Gawlik K; Schwaab J; Michaely HJ; Metzgeroth G; Hofmann WK; Schoenberg SO; Reiter A
Ann Hematol; 2019 Dec; 98(12):2693-2701. PubMed ID: 31686155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
